Quai.MD

Name: Quai.MD
Brand: Quai.MD

Quai.MD develops a unique AI-based platform to help doctors diagnose patients accurately in real time

LinkedIn 913|Website|FTEs 25|HQ Tel Aviv, Tel-Aviv District, IL

Published Oct 15, 2026

01Common complaints

1. Organizations that require extensive public peer-benchmarking and abundant third-party product reviews before engagement. - Public review coverage on G2/TrustRadius/Gartner Peer Insights was limited in accessible sources at the time of research. 2. Organizations that require publicly available compliance attestations (for example, SOC 2 or ISO 27001) to be published prior to any vendor engagement. - Independent security attestations were not clearly published on the vendor website in accessible pages during this research. 3. Organizations seeking a pure ambient note-generation solution with minimal embedded workflow guidance. - Scribe-first vendors may be simpler to evaluate if the priority is transcription and note generation rather than embedded pathway support. 4. Organizations that cannot tolerate integration or program risk. - EHR-embedded tools commonly involve governance, integration development, and workflow validation; these projects can experience delays.

Deal disqualifiers (poor fit)

Very small EDs without internal integration resources.
Organizations unable or unwilling to complete vendor risk and security requirements.
Sites where clinicians are strongly opposed to in-workflow decision support.

Publicly visible limitations

Pricing is not publicly posted, which complicates pre-qualification.
Security certifications and independent attestations are not clearly documented on publicly accessible site pages.
Limited third-party user reviews on major software review platforms.

Likely operational limitations (inferred)

EHR integration and governance timelines can be lengthy.
The vendor does not publicly disclose technical integration details (for example, whether the workflow is delivered via SMART-on-FHIR, an embedded frame, HL7 feeds, or another method); buyers should verify the technical approach during evaluation.

02Why they buy

Vendor-reported differentiators

ED-focused workflow guidance combining differential/workup recommendations with embedded documentation generation, according to vendor messaging.
Documentation features described as aligned with coding and billing considerations (vendor language refers to MDM alignment).
Integration approach marketed as embedded in the EHR to reduce context switching compared with standalone applications.

What is not yet validated publicly

Measurable outcomes referenced in vendor messaging are not fully supported by publicly available, peer-reviewed studies or detailed outcome datasets.

Source: https://quai.md/

03Field reports

Review platform coverage

No Quai.MD product listings with user reviews were identified on common SaaS review platforms during this research, including G2, TrustRadius, Capterra, and Gartner Peer Insights. Publicly accessible search results did not surface peer reviews on those platforms.

Sources (platform pages):

Official platform home pages (Gartner Peer Insights, TrustRadius)

Vendor- or partner-published testimonial

The Quai.MD website includes at least one vendor-published physician testimonial describing the product as supporting structured diagnostic thinking and non-interruptive workflow support. This testimonial is presented by the vendor and has not been independently corroborated in publicly available peer-reviewed literature.

Source: Official vendor website

Community and social discussion

Direct community discussion specific to Quai.MD on platforms such as Reddit or Hacker News was not readily discoverable. Broader community discussions about ED workflow and AI in clinical workflows indicate clinician interest and also skepticism about over-reliance, potential workflow burden, and implementation complexity.

Example context (not Quai-specific): Community discussion thread example (public forum)

Employment reviews (culture/operations signal)

A Glassdoor page exists for Quai.MD, which may provide insight into company culture and operations; this is not a product review source.

Source: Employment review site page (Glassdoor)

Implication: Public, third-party product reviews are limited; references and pilot data are likely to be primary validation sources for procurement.

MUSC pilot (public institutional mention)

A MUSC board/president report references a pilot of the Quai.MD application in MUSC emergency departments. Publicly available summaries are limited; the report confirms a pilot but does not provide detailed outcomes or study methodology. Source: Official institutional board/president report (PDF) Critical evaluation: - The pilot indicates institutional interest and operational testing. - Public materials do not include rigorous outcome measures (for example, diagnostic error reduction, length of stay, or revenue metrics) or methodological details.

HITLAB evaluation / whitepaper

HITLAB published a whitepaper and partner announcement evaluating Quai.MD. The whitepaper represents an external organization’s assessment but was conducted in partnership with the vendor, and procurement teams should treat it accordingly until methods and raw data are made available. Sources: - HITLAB vendor-partner announcement - HITLAB whitepaper (PDF) from the external evaluator Critical evaluation: - Buyers should review the whitepaper for sample size, scoring methodology, simulated versus in-production testing, and whether clinical outcomes were measured versus usability heuristics.

Mayo Clinic-related announcements

Partner communications reference an introduction of the product at Mayo Clinic, which may represent a pilot or collaborative evaluation. Public references do not clearly indicate the scope (single department versus enterprise) or whether the activity is evaluation-only or a production deployment. Source: Partner communications / public announcement Critical evaluation: - The presence of Mayo Clinic in partner communications suggests institutional evaluation, but details on scope and outcomes are not publicly documented.

04Best fit

Organization sizes

Likely best fit candidates include:

Mid-to-large health systems with sufficient ED volume to justify integration effort and governance overhead.
Multi-site ED groups pursuing standardization and documentation improvements.

Typical ICP inferred from integration economics: hospitals or health systems with ED groups ranging from tens to low‑hundreds of clinicians across sites.

Source: Official vendor website

Settings

Emergency Medicine (primary focus identified in vendor materials).
Potential applicability in acute or urgent care settings, subject to local protocol adaptation.

Roles and personas

Decision makers: CMIO, ED chair/medical director, quality/safety leadership, and revenue cycle leadership.
Influencers: frontline ED physicians, nursing leadership, and clinical informatics teams.
Implementers: integration engineers, Epic/Cerner analysts, and security/compliance staff.

Qualification criteria (good fit)

Organizations with internal governance capable of running controlled pilots.
Groups willing to undertake workflow change and pathway standardization.
Buyers with a defined ROI hypothesis such as documentation completeness, time-to-bill, or variability reduction.

05The pitch

What the product does (objective core value proposition)

Quai.MD is an EHR-embedded clinical workflow platform that uses artificial intelligence and is focused primarily on emergency department (ED) care. Vendor materials describe the following capabilities: - Point-of-care clinical guidance for assessment, differential diagnosis suggestions, and recommended workup steps. - Embedded pathways intended to reduce variation in care by aligning clinician workflow to documented protocols. - Automated generation of Medical Decision Making (MDM) documentation inside the EHR, with an emphasis on supporting coding and billing processes. These descriptions are drawn from vendor and partner publications; independent clinical-outcomes validation is limited in publicly available sources. Sources: - Product overview and feature pages published by the vendor - Trademark registration summary describing software functions and EHR protocols - Industry partnership announcement describing EHR-embedded pathways

Target market and positioning

Quai.MD is marketed to: - Hospitals and health systems, with an initial focus on Emergency Medicine settings. - Clinical leadership stakeholders (CMIO, ED leadership, quality/safety) and revenue-cycle stakeholders concerned with documentation and billing completeness. - Organizations seeking an EHR-integrated workflow support tool rather than a standalone transcription/scribe application. Vendor messaging indicates the product integrates medical knowledge, patient data, and workflow pathways rather than functioning solely as an ambient transcription tool. Source: Vendor product site and marketing materials

Get a comprehensive analysis of Quai.MD including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →

Published Oct 15, 2026

01Common complaints

Organizations that require extensive public peer-benchmarking and abundant third-party product reviews before engagement.
- Public review coverage on G2/TrustRadius/Gartner Peer Insights was limited in accessible sources at the time of research.
Organizations that require publicly available compliance attestations (for example, SOC 2 or ISO 27001) to be published prior to any vendor engagement.
- Independent security attestations were not clearly published on the vendor website in accessible pages during this research.
Organizations seeking a pure ambient note-generation solution with minimal embedded workflow guidance.
- Scribe-first vendors may be simpler to evaluate if the priority is transcription and note generation rather than embedded pathway support.
Organizations that cannot tolerate integration or program risk.
- EHR-embedded tools commonly involve governance, integration development, and workflow validation; these projects can experience delays.

Deal disqualifiers (poor fit)

Very small EDs without internal integration resources.
Organizations unable or unwilling to complete vendor risk and security requirements.
Sites where clinicians are strongly opposed to in-workflow decision support.

Publicly visible limitations

Pricing is not publicly posted, which complicates pre-qualification.
Security certifications and independent attestations are not clearly documented on publicly accessible site pages.
Limited third-party user reviews on major software review platforms.

Likely operational limitations (inferred)

EHR integration and governance timelines can be lengthy.
The vendor does not publicly disclose technical integration details (for example, whether the workflow is delivered via SMART-on-FHIR, an embedded frame, HL7 feeds, or another method); buyers should verify the technical approach during evaluation.

02Why they buy

Vendor-reported differentiators

ED-focused workflow guidance combining differential/workup recommendations with embedded documentation generation, according to vendor messaging.
Documentation features described as aligned with coding and billing considerations (vendor language refers to MDM alignment).
Integration approach marketed as embedded in the EHR to reduce context switching compared with standalone applications.

What is not yet validated publicly

Measurable outcomes referenced in vendor messaging are not fully supported by publicly available, peer-reviewed studies or detailed outcome datasets.

Source: https://quai.md/

03Field reports

Review platform coverage

Sources (platform pages):

Official platform home pages (Gartner Peer Insights, TrustRadius)

Vendor- or partner-published testimonial

Source: Official vendor website

Community and social discussion

Example context (not Quai-specific): Community discussion thread example (public forum)

Employment reviews (culture/operations signal)

A Glassdoor page exists for Quai.MD, which may provide insight into company culture and operations; this is not a product review source.

Source: Employment review site page (Glassdoor)

Implication: Public, third-party product reviews are limited; references and pilot data are likely to be primary validation sources for procurement.

MUSC pilot (public institutional mention)

Source: Official institutional board/president report (PDF)

Critical evaluation:

The pilot indicates institutional interest and operational testing.
Public materials do not include rigorous outcome measures (for example, diagnostic error reduction, length of stay, or revenue metrics) or methodological details.

HITLAB evaluation / whitepaper

Sources:

HITLAB vendor-partner announcement
HITLAB whitepaper (PDF) from the external evaluator

Critical evaluation:

Buyers should review the whitepaper for sample size, scoring methodology, simulated versus in-production testing, and whether clinical outcomes were measured versus usability heuristics.

Mayo Clinic-related announcements

Source: Partner communications / public announcement

Critical evaluation:

The presence of Mayo Clinic in partner communications suggests institutional evaluation, but details on scope and outcomes are not publicly documented.

04Best fit

Organization sizes

Likely best fit candidates include:

Mid-to-large health systems with sufficient ED volume to justify integration effort and governance overhead.
Multi-site ED groups pursuing standardization and documentation improvements.

Typical ICP inferred from integration economics: hospitals or health systems with ED groups ranging from tens to low‑hundreds of clinicians across sites.

Source: Official vendor website

Settings

Emergency Medicine (primary focus identified in vendor materials).
Potential applicability in acute or urgent care settings, subject to local protocol adaptation.

Roles and personas

Decision makers: CMIO, ED chair/medical director, quality/safety leadership, and revenue cycle leadership.
Influencers: frontline ED physicians, nursing leadership, and clinical informatics teams.
Implementers: integration engineers, Epic/Cerner analysts, and security/compliance staff.

Qualification criteria (good fit)

Organizations with internal governance capable of running controlled pilots.
Groups willing to undertake workflow change and pathway standardization.
Buyers with a defined ROI hypothesis such as documentation completeness, time-to-bill, or variability reduction.

05The pitch

What the product does (objective core value proposition)

Point-of-care clinical guidance for assessment, differential diagnosis suggestions, and recommended workup steps.
Embedded pathways intended to reduce variation in care by aligning clinician workflow to documented protocols.
Automated generation of Medical Decision Making (MDM) documentation inside the EHR, with an emphasis on supporting coding and billing processes.

These descriptions are drawn from vendor and partner publications; independent clinical-outcomes validation is limited in publicly available sources.

Sources:

Product overview and feature pages published by the vendor
Trademark registration summary describing software functions and EHR protocols
Industry partnership announcement describing EHR-embedded pathways

Target market and positioning

Quai.MD is marketed to:

Hospitals and health systems, with an initial focus on Emergency Medicine settings.
Clinical leadership stakeholders (CMIO, ED leadership, quality/safety) and revenue-cycle stakeholders concerned with documentation and billing completeness.
Organizations seeking an EHR-integrated workflow support tool rather than a standalone transcription/scribe application.

Vendor messaging indicates the product integrates medical knowledge, patient data, and workflow pathways rather than functioning solely as an ambient transcription tool.

Source: Vendor product site and marketing materials

Get a comprehensive analysis of Quai.MD including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →